Background: Gleason scores from standard, 12-core prostate biopsies are upgraded historically in 25À33% of patients. Multiparametric prostate magnetic resonance imaging (MP-MRI) with ultrasound (US)-targeted fusion biopsy may better sample the true gland pathology. Objective: The rate of Gleason score upgrading from an MRI/US-fusion-guided prostatebiopsy platform is compared with a standard 12-core biopsy regimen alone. Design, setting, and participants: There were 582 subjects enrolled from
1.

Introduction
Pathologic grading of prostate cancer (PCa) based on biopsy Gleason score (bGS) plays an important role in clinical decision making. Unfortunately, a number of studies have identified a poor correlation between the Gleason score identified on prostate biopsy and that found in the prostatectomy specimen, with rates of Gleason score upgrading between 21% and 54% [1] [2] [3] . Cookson and colleagues have also reported a discrepancy of two or more grades in 26% of cases [4] . The challenge is that surgical-specimen Gleason scores are obtained too late (after the surgery) to influence decision making, algorithms, and triage that involve surgery. Multiparametric prostate magnetic resonance imaging (MP-MRI) has emerged as an accurate modality in detecting PCa. Lesions identified on MP-MRI correlate with tumor location on radical prostatectomy specimens [5] . A similar study found that the level of radiologic suspicion based on MP-MRI findings correlates with the D'Amico risk stratification [6] .
The ability to detect, delineate, and measure PCa on magnetic resonance imaging (MRI) has led to the development of three MRI-guided prostate biopsy methods: cognitive fusion, direct MRI-guided biopsy, and several methods of MRI/ultrasound (MRI/US)-fusion-guided biopsy [7] . Cognitive fusion involves an estimation of the location of the lesion on the part of the transrectal ultrasound (TRUS) operator and varies greatly with expertise. Direct MRI-guided biopsy is time consuming and resource costly. In contrast, MRI/US-fusion-guided biopsy is an outpatient procedure, in which prebiopsy MRI of the prostate is segmented, registered, and fused with real-time ultrasound using electromagnetic tracking or mechanical-arm navigation and a digital overlay. This method integrates well with current workflow patterns of TRUS-guided biopsy yet provides a platform for a targeted approach to prostate biopsy based on MRI-identified targets and lesions [8] . MRI/US-fusion-guided biopsy has the potential to offer improved diagnostic information over 12-core biopsy alone. To study whether MRI/US fusion results in more accurate biopsies, the correlation was assessed between the Gleason scores detected on MRI/US-fusion biopsy and those found on a standard 12-core TRUS biopsy performed during the same biopsy session.
2.
Patients and methods
Study population
Subjects were enrolled in a prospective trial assessing MRI/US-fusionguided prostate biopsy with electromagnetic tracking at the US National Medrad Inc., Pittsburgh, PA, USA), as previously described [10, 11] . These diagnostic MP-MRI studies underwent blinded, centralized radiologic evaluation to identify lesions if present and to assign PCa suspicion scores to each lesion (low, moderate, and high) according to previously described criteria [9] . Two genitourinary radiologists (B.T. and P.L.C.) with 7 yr and 13 yr, respectively, of experience interpreting prostate MRI performed independent review and formed consensus reads of all MP-MRI in this series.
Biopsy protocol
Subjects with lesions suspicious for PCa on MP-MRI underwent prostate biopsy as previously described [12] . A standard 12-core TRUS-guided biopsy was performed (blinded to the MRI target lesions) in conjunction with a fusion biopsy using the prebiopsy MP-MRI images, which were 
Data analysis
The Student t test and Pearson x 2 or Fisher exact test were used to determine differences between continuous and categorical variables, respectively. Logistic regression models were used for univariate and multivariable analysis. JMP Pro v.10.0 (SAS Institute Inc., Cary, NC, USA)
was used for statistical analysis.
Results
Patient demographics of the study cohort are shown in Table 1 . The mean age of the patient population was 61.3 yr and mean prebiopsy PSA level was 9.9 ng/ml. The mean number of targeted biopsies per patient was 5.7, and, accordingly, the mean total number of biopsies including the standard 12-cores was 17.7. Abnormal findings on TRUS were observed in 79 (14%) of subjects. The rate of Gleason score upgrading with targeted MRI/US-fusion-guided prostate biopsy was compared with standard 12-core biopsy alone. The cohort was divided into clinically significant high-grade (Gleason score !4 + 3) and clinically insignificant low-grade (Gleason score 3 + 4) subcohorts in accordance with the Standards of Reporting for MRI-targeted Biopsy Studies (START) working group recommendations [13] . A distribution of bGS as seen on standard 12-core biopsy versus MRI/US-fusion guided biopsy can be seen in Table 2 . Gleason score upgrading was observed in 81 cases (32% of the 255 PCa cases diagnosed on 12-core biopsy alone). Targeted biopsies resulted in 43 (22% of 198 cases) additional cases of Gleason 3 + 4 PCa and 38 (67% of 57 cases) additional cases of clinically significant PCa (Gleason !4 + 3) ( Table 3 ).
In contrast, we examined the converse scenario of additional cases of PCa diagnosed by standard extended 12-core TRUS biopsy versus the targeted biopsy alone. Gleason score upgrading was found in 67 patients (26% of 253 cases) by 12-core biopsies when compared with targeted biopsies alone. An additional 60 of 165 cases (36%) of Gleason 3 + 4 PCa cases and 7 of 88 cases (8%) of additional Gleason !4 + 3 PCa were diagnosed by 12-core biopsies when compared with the targeted biopsy platform alone ( Table 3) .
The distribution of bGS diagnosed by targeted biopsy was examined for each given 12-core bGS (Fig. 2a) . Of note, one patient (1% of all bGS !8) had a bGS !8 PCa by 12-core biopsy but had no cancer detected on targeted biopsy. In addition, 15 patients (15% of all bGS 7) with bGS 7 PCa on 12-core had no cancer detected on targeted biopsy (14 of these 15 were bGS 3 + 4). Conversely, 14 patients (17% of subjects with bGS !8) with no cancer on the 12-core biopsy were diagnosed with bGS !8 by targeted biopsy, and an additional 21 patients (21% of subjects with bGS 7) with no cancer on 12-core biopsy were diagnosed with bGS 7 PCa (18 of these 21 were bGS 3 + 4) (Fig. 2b) . Overall, 17 patients with Gleason score !4 + 3 disease (5% of all patients with cancer and 18% of patients with bGS !4 + 3) would have been misdiagnosed as having no cancer if they had been assessed by the standard 12-core biopsy alone. Figure 3 demonstrates the distribution of cases missed by 12-core biopsy and targeted biopsy.
Potential predictors of Gleason score upgrading on targeted biopsy were assessed. Using univariate analysis, decreased prostate volume, higher PSA level, higher number of lesions on MRI, and higher MRI suspicion level were all associated with Gleason score upgrading by MRI/US-fusionguided biopsy and remained significant on multivariate analysis. MRI suspicion had the strongest association with Gleason score upgrading by targeted biopsy (odds ratio [OR]: 1.7; p = 0.04) but higher PSA level, lower prostate volume, and more lesions on MRI were also significantly associated with Gleason score upgrading ( Table 4 ). The [ MRI-US = magnetic resonance imaging/ultrasound. * Clinically insignificant defined as Gleason score 7 (3 + 4) and clinically significant defined as Gleason score !7 (4 + 3).
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number of biopsy cores performed may be an important confounder, and further controlling for number of total cores resulted in the number of lesions on MRI no longer being associated with Gleason score upgrading (p = 0.6). PSA level, prostate volume, and MRI suspicion (OR: 1.7; p < 0.05), however, remained associated with Gleason score upgrading by targeted biopsy (Table 5) . Last, we also examined maximal percent cancer-positive cores and found a significant difference between targeted biopsy and 12-core biopsy cores (47.5 AE 35.1% for targeted, 9.2 AE 20.3% for 12-core p < 0.0001).
Discussion
There has been considerable concern regarding overdiagnosis and subsequent overtreatment of men with clinically indolent PCa; thus, better characterization of PCa is highly desirable [14] . MRI/US-fusion-guided, targeted biopsies may potentially offer such an improvement [15] . An initial cohort in this same clinical trial previously demonstrated that MRI/US-fusion-guided targeted biopsy increased cancer detection rates significantly compared with standard 12-core TRUS biopsy alone, especially in lesions with a high level of suspicion on the MRI [12] . Studies have found that MRI/US-fusion biopsy detected PCa in 34-37% of patients with prior negative TRUS biopsies, with one-third of these patients harboring high-grade cancer defined as Gleason score of !8 [10, 16] . In this study, the rate of Gleason score upgrading by targeted biopsy versus standard, extended 12-core biopsies was characterized. Use of the targeted biopsy as an adjunct to the standard 12-core biopsy resulted in a 32% rate of Gleason score upgrading compared with the 12-core biopsy alone. We also found that a large number of bGS !4 + 3 PCa (17 patients, 18% of patients with Gleason !4 + 3) would have been diagnosed as no cancer based solely on the 12-core biopsy data. To assess the utility of the standard 12-core biopsy in conjunction with the fusion-guided biopsies, we also examined the rate of Gleason score upgrading by 12-core biopsy when compared with target biopsy alone. Standardtemplate 12-core biopsies detected some tumors not picked up on targeted biopsy, which is consistent with prior findings, although most of these were bGS 3 + 4. Our current practice is to add fusion biopsies to the standard 12-core biopsy, rather than replacing the standard 12-core altogether. There was a 26% rate of Gleason score upgrading with 12-core biopsies compared with targeted biopsies; 2.1 0.9-6.1 0.1 ---OR = odds ratio; CI = confidence interval; PSA = prostate-specific antigen; MRI = magnetic resonance imaging; TRUS = transrectal ultrasound; DRE = digital rectal examination. Biopsy cores (per core), no.
1.1 0.9-1.3 0.6 OR = odds ratio; CI = confidence interval; PSA = prostate-specific antigen; MRI = magnetic resonance imaging.
[ ( F i g . _ 3 ) T D $ F I G ] Fig. 3 -Distribution of cases missed by 12-core biopsy and targeted biopsy.
most of these cancers (46 of 67 patients [69%]) were upgraded from no cancer on targeted biopsy to bGS 6 cancer on 12-core biopsy. These data thus support the use of MRI/US-fusion targeted biopsy in the diagnosis of clinically significant high-grade disease without significantly adding to the diagnosis of low-grade, clinically indolent disease. Furthermore, improved targeting with the MRI/US fusion resulted in significantly longer cancer core lengths. Although core length was not incorporated into the definitions of clinically significant and insignificant disease in this study, which was focused on Gleason score upgrading, maximum cancercore length has been recommended by experts as an important variable to incorporate into the measure of clinical significance of PCa [13] . The fusion platform was more useful in patients with high suspicion levels as judged on MP-MRI, as well as in patients with higher PSA levels, and smaller prostates. This raises the question of whether targeted biopsies could be performed in lieu of the standard 12-core biopsy. Although in our study the 12-core biopsy increased the rate of diagnosis of Gleason 6 PCa, which may be an undesirable result, it did have significant utility in the diagnosis of Gleason grade 7 PCa (37% increased rate of diagnosis compared with targeted biopsy alone). Most of these were bGS 3 + 4 (14 of 15 patients). Further research is needed and adding the fusion biopsy to the standard 12-core biopsy remains our current practice in most patients until the emergence of more clear data. Of interest also was a subcohort of seven patients in which 12-core biopsy detected clinically significant bGS !4 + 3 PCa not detected on targeted biopsy. Review of these patients could not definitively demonstrate failure to diagnose on MP-MRI versus targeted biopsy technique; perhaps poor image registration or targeting was the cause for this discordance. This finding raises the larger question of interest regarding imaging-guided modalities of whether upgrading was generally due to improved targeted sampling of areas of tumor that were only partially sampled on 12-core biopsy or due to improved localization on imaging of tumor that would have otherwise not been sampled altogether. Our brief review of the data suggests both scenarios may play a factor, but this question was outside the scope of this study, and clearly future, dedicated studies are needed to address this significant question.
A limitation of this study is that it compares two biopsy modalities to each other. Ideally, the addition of final prostatectomy pathology as an end point arbitrates which lesions were most important to detect. Data acquisition to address this limitation is under way. Another limitation stems from the fact that the referral population in this study usually presented with an elevated PSA level that had prompted prior negative biopsies. Thus, the population is skewed to patients who would be more likely to benefit from targeted biopsies. This selection bias suggests that these findings may not be generalizable to the general population of men undergoing biopsy, although this too is speculative. Last, the inclusion criteria of the trial specified patients with MRI-visible lesions, thus excluding patients with no lesions seen on MRI. Due to this limitation, although it likely applies to few subjects, we were not able to ascertain how many patients with no lesions on MP-MRI had cancer and, in particular, high-grade cancers.
Conclusions
In this study, the rate of Gleason score upgrading with MRI/ US-fusion-guided targeted biopsies was examined and a 32% rate of increased Gleason score was found when compared with standard extended 12-core biopsy alone. The converse relationship was also examined of 12-core biopsies as an adjunct to targeted biopsies alone and found a 26% rate of Gleason score upgrading. Most of these cases were due to new bGS 6 tumors that were detected; however, seven patients were upgraded to bGS !4 + 3 disease. MP-MRI suspicion level was found to have a strong association with Gleason score upgrading by targeted biopsy (over 12-core biopsy). MRI/US-fusion targeted biopsy missed far fewer aggressive PCa tumors than standard biopsy. This study highlights a potentially useful role of MRI/US-fusion-guided targeted biopsies for the identification of clinically significant high-risk tumors otherwise missed by 12-core biopsy alone.
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